DK1772464T3 - Fremgangsmåder til identificering af indirekte agonister af IGF-1 - Google Patents

Fremgangsmåder til identificering af indirekte agonister af IGF-1

Info

Publication number
DK1772464T3
DK1772464T3 DK06026832T DK06026832T DK1772464T3 DK 1772464 T3 DK1772464 T3 DK 1772464T3 DK 06026832 T DK06026832 T DK 06026832T DK 06026832 T DK06026832 T DK 06026832T DK 1772464 T3 DK1772464 T3 DK 1772464T3
Authority
DK
Denmark
Prior art keywords
igf
methods
indirect agonists
identifying
identifying indirect
Prior art date
Application number
DK06026832T
Other languages
English (en)
Inventor
Michelle Schaffer
Mark Ultsch
Felix Vajdos
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1772464T3 publication Critical patent/DK1772464T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
DK06026832T 2001-02-09 2002-02-01 Fremgangsmåder til identificering af indirekte agonister af IGF-1 DK1772464T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26797701P 2001-02-09 2001-02-09
US28707201P 2001-04-27 2001-04-27
PCT/US2002/003156 WO2002064627A2 (en) 2001-02-09 2002-02-01 Crystallization of igf-1

Publications (1)

Publication Number Publication Date
DK1772464T3 true DK1772464T3 (da) 2009-12-14

Family

ID=26952796

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02724908T DK1358209T3 (da) 2001-02-09 2002-02-01 Krystallisering af IGF-1
DK06026832T DK1772464T3 (da) 2001-02-09 2002-02-01 Fremgangsmåder til identificering af indirekte agonister af IGF-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02724908T DK1358209T3 (da) 2001-02-09 2002-02-01 Krystallisering af IGF-1

Country Status (19)

Country Link
US (8) US7084240B2 (da)
EP (3) EP1772464B1 (da)
JP (2) JP4489352B2 (da)
KR (1) KR100872613B1 (da)
CN (1) CN100439397C (da)
AT (2) ATE349469T1 (da)
AU (1) AU2002255508B2 (da)
BR (1) BR0207422A (da)
CA (1) CA2431033A1 (da)
DE (3) DE60217066T4 (da)
DK (2) DK1358209T3 (da)
ES (2) ES2278020T3 (da)
HU (1) HUP0500733A3 (da)
IL (2) IL156435A0 (da)
MX (1) MXPA03007042A (da)
NZ (3) NZ548359A (da)
PL (1) PL374181A1 (da)
WO (1) WO2002064627A2 (da)
ZA (1) ZA200304900B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071300B2 (en) * 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
AU2002324672B2 (en) * 2001-09-18 2007-11-08 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US6914049B2 (en) * 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
WO2004102151A2 (en) * 2003-05-06 2004-11-25 New Century Pharmaceuticals Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on therir albumin binding properties
WO2005041895A2 (en) * 2003-11-03 2005-05-12 New Century Pharmaceuticals, Inc. Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
EP1706128B1 (en) 2003-12-08 2010-07-21 CPEX Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment
US20060069019A1 (en) * 2004-05-06 2006-03-30 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor beta chain with Met receptor and methods of use
WO2006001911A2 (en) * 2004-05-06 2006-01-05 Genentech, Inc. Crystal structure of the hepatocyte growth factor beta chain and methods of use
BRPI0513508B1 (pt) 2004-07-19 2021-06-01 Biocon Limited Conjugados de insulina-oligômero, formulações e usos desses
JP2008514240A (ja) * 2004-10-01 2008-05-08 インヴィトロジェン コーポレーション 生体分子のインビトロ合成用の供給バッファー、系、及び方法
US7556776B2 (en) * 2005-09-08 2009-07-07 President And Fellows Of Harvard College Microfluidic manipulation of fluids and reactions
JP2010529128A (ja) * 2007-06-08 2010-08-26 マサチューセッツ インスティテュート オブ テクノロジー レット症候群および他の障害の処置
US8350007B2 (en) 2007-08-17 2013-01-08 The Regents Of The University Of California Crystal structure of human mitoNEET protein
CN101139391B (zh) * 2007-08-21 2012-07-25 陈志南 Cd147胞外区晶体结构及应用
WO2009134395A2 (en) 2008-04-28 2009-11-05 President And Fellows Of Harvard College Microfluidic device for storage and well-defined arrangement of droplets
WO2011011071A2 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
CA2768621C (en) 2009-07-22 2016-04-05 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59
US20120266263A1 (en) * 2009-10-14 2012-10-18 Mount Sinai School Of Medicine Method of treating memory disorders and enhancing memory using igf-ii compounds
WO2013148227A1 (en) * 2012-03-28 2013-10-03 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
KR101711584B1 (ko) * 2012-12-18 2017-03-02 재단법인 의약바이오컨버젼스연구단 변형된 eprs 단백질의 결정 구조 및 이의 결정화 방법
US10279013B2 (en) 2013-12-19 2019-05-07 Puretein Bioscience Llc Methods for treating an animal
JP2022547948A (ja) 2019-09-09 2022-11-16 ザ・ユニバーシティ・オブ・シカゴ 片頭痛の処置のための併用療法
US20240050455A1 (en) * 2020-06-01 2024-02-15 Loma Linda University Health Methods of treatment of a cytokine storm
WO2025259950A1 (en) * 2024-06-14 2025-12-18 Cz Biohub Sf, Llc Genetically encoded lysosome targeting chimeras for cell-mediated delivery

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US589867A (en) * 1897-09-14 Clothes-line hanger
US577276A (en) * 1897-02-16 Quarter-saver iv
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
JPH0720993B2 (ja) * 1985-08-22 1995-03-08 グロペップ プロプライエタリー リミテッド 生長因子
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5470828A (en) * 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US5164370A (en) * 1987-12-24 1992-11-17 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
ATE86496T1 (de) * 1988-02-05 1993-03-15 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5028224A (en) * 1990-01-09 1991-07-02 Kimberly-Clark Corporation Apparatus for intermittently depositing particulate material in a substrate
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
DE69218948T2 (de) * 1991-08-01 1997-07-31 Auckland Uniservices Ltd IGF-I zur Verbesserung der neuronale Lage
US5126314A (en) * 1991-09-06 1992-06-30 Eastman Kodak Company Mixture of dyes for black dye donor for thermal color proofing
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
JPH07508025A (ja) 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
EP0955365A3 (en) 1992-06-09 2000-12-20 Chiron Corporation Crystallization of M-CSF
ES2140463T3 (es) 1992-06-12 2000-03-01 Cephalon Inc Prevencion y tratamiento de la neuropatia periferica.
GB9217696D0 (en) 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
WO1994016722A1 (en) 1993-01-25 1994-08-04 The Beth Israel Hospital Association Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
DK72793D0 (da) 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
US5407810A (en) 1993-08-20 1995-04-18 Genentech, Inc. Aqueous multiple-phase isolation of polypeptide
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
PT833847E (pt) 1995-06-22 2004-02-27 Biogen Inc Cristais de fragmentos de ligando cd40 e sua utilizacao
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
JP3417230B2 (ja) * 1996-09-25 2003-06-16 信越化学工業株式会社 型取り母型用光硬化性液状シリコーンゴム組成物
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
WO1999001476A1 (en) 1997-07-03 1999-01-14 Smithkline Beecham Corporation CRYSTAL STRUCTURES OF ANTI-FACTOR IX Fab FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN
US5876242A (en) * 1997-07-21 1999-03-02 Williams; Hugh D. Remote battery extension apparatus
AU764858B2 (en) 1998-01-21 2003-09-04 Brigham And Women's Hospital Circulating insulin-like growth factor-I and prostate cancer risk
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
WO2001072771A2 (en) 2000-03-29 2001-10-04 Dgi Biotechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists
CA2449290A1 (en) 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag Mutants of igf binding proteins and methods of production of antagonists thereof
US20040137518A1 (en) * 2002-01-31 2004-07-15 Lambert Millard Hurst CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME
JP3680801B2 (ja) * 2002-02-27 2005-08-10 株式会社デンソー 回転電機の巻線接合方法

Also Published As

Publication number Publication date
DE60233359D1 (de) 2009-09-24
EP1772464A2 (en) 2007-04-11
WO2002064627A2 (en) 2002-08-22
NZ548358A (en) 2008-04-30
DE60217066D1 (de) 2007-02-08
HK1060138A1 (en) 2004-07-30
BR0207422A (pt) 2005-04-19
CA2431033A1 (en) 2002-08-22
US7297763B2 (en) 2007-11-20
JP2009215299A (ja) 2009-09-24
AU2002255508B2 (en) 2008-04-03
ATE349469T1 (de) 2007-01-15
HUP0500733A3 (en) 2010-01-28
CN1703425A (zh) 2005-11-30
US20020165155A1 (en) 2002-11-07
US20050215477A1 (en) 2005-09-29
DE60217066T4 (de) 2010-07-01
NZ548359A (en) 2007-11-30
US20060281905A1 (en) 2006-12-14
US7433788B2 (en) 2008-10-07
KR100872613B1 (ko) 2008-12-09
MXPA03007042A (es) 2004-05-24
ES2331150T3 (es) 2009-12-22
US20060293507A1 (en) 2006-12-28
US20060287235A1 (en) 2006-12-21
HUP0500733A2 (hu) 2005-10-28
CN100439397C (zh) 2008-12-03
ES2278020T3 (es) 2007-08-01
US20060270839A1 (en) 2006-11-30
KR20040064610A (ko) 2004-07-19
WO2002064627A3 (en) 2003-07-31
EP1801120A1 (en) 2007-06-27
DK1358209T3 (da) 2007-05-07
ATE439378T1 (de) 2009-08-15
DE60217066T2 (de) 2007-07-12
PL374181A1 (en) 2005-10-03
US7238658B2 (en) 2007-07-03
IL156435A (en) 2009-09-22
IL156435A0 (en) 2004-01-04
EP1358209A2 (en) 2003-11-05
US20060276397A1 (en) 2006-12-07
NZ526672A (en) 2006-10-27
US7596455B2 (en) 2009-09-29
JP2005503329A (ja) 2005-02-03
EP1358209B1 (en) 2006-12-27
US7354769B2 (en) 2008-04-08
US20060287510A1 (en) 2006-12-21
EP1772464A3 (en) 2007-10-03
ZA200304900B (en) 2005-07-27
JP4489352B2 (ja) 2010-06-23
EP1772464B1 (en) 2009-08-12
US7084240B2 (en) 2006-08-01

Similar Documents

Publication Publication Date Title
DK1772464T3 (da) Fremgangsmåder til identificering af indirekte agonister af IGF-1
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
ATE479175T1 (de) Bereitstellung von verkehrsinformationen mit unterverknüpfungen von verknüpfungen
DK1409459T3 (da) ECL mærker, som har forbedrede, non-specifikke bindingsegenskaber, fremgangsmåder til anvendelse deraf, og kits indeholdende samme.
ATE343591T1 (de) Antagonist für die multimerisierung von hiv-1 vif-protein
BRPI0413070A (pt) métodos e sistemas para entender um significado de um item de conhecimento, usando informação associada com o item de conhecimento
ATE425643T1 (de) Verfahren und system zum halten einer sitzungskontinuität
TW200633487A (en) Access rights
NO20064194L (no) Fremgangsmate for a modulere IL-23-aktivitet, beslektede reagenser
MX2025010000A (es) Ensayos sandwich de colocalizacion por enlace
ATE424560T1 (de) Marker für neuromyelitis optica
DK1423541T3 (da) Fremgangsmåde til at bestemme multiple analytter
WO2008060483A3 (en) Protein-protein interaction biosensors and methods of use thereof
DE602004032466D1 (de) Durchführung von prüfungen an der betriebsmittelbenutzung von computerprogrammen
BR0116847B1 (pt) sistema de elevador, e, mÉtodo para inspecionar pelo menos uma correia em um sistema de elevador.
BRPI0414365A (pt) composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes
DE60332029D1 (de) Screening-verfahren für kognitive erweiterungsvorrichtungen
NO20052553L (no) Cobalaminanalyse.
FI20031191A7 (fi) Monoamiinin takaisinoton estäjä
DK1224222T3 (da) Chemokinreceptor
BR0300368B1 (pt) máscara, dispositivo e método para depositar reagentes sobre um suporte analítico para amostras biológicas, método para detectar os constituintes de uma ou mais amostras biológicas por imunofixação, e, kit.
ATE301833T1 (de) Verfahren zum screenen einer die oligomerisierung von rezeptorproteinmolekülen fördernden substanz
DE60040010D1 (de) Ein Verfahren zum Auffinden vom Prostatakrebs
BRPI0413610A (pt) método para a identificação de agonistas ou inibidores da proteìna quinase irs
WO2004048518A3 (en) Organelle-associated proteins